3/19
09:00 am
aldx
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
High
Report
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
3/18
05:28 pm
aldx
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
High
Report
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
3/18
01:38 pm
aldx
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA [Yahoo! Finance]
Low
Report
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA [Yahoo! Finance]
3/18
08:03 am
aldx
Aldeyra Therapeutics (ALDX) had its "neutral" rating reaffirmed by HC Wainwright. They now have a $2.00 price target on the stock, down from $10.00.
High
Report
Aldeyra Therapeutics (ALDX) had its "neutral" rating reaffirmed by HC Wainwright. They now have a $2.00 price target on the stock, down from $10.00.
3/18
06:20 am
aldx
FDA issues CRL to Aldeyra's reproxalap drug application [Yahoo! Finance]
High
Report
FDA issues CRL to Aldeyra's reproxalap drug application [Yahoo! Finance]
3/17
06:07 pm
aldx
Aldeyra Therapeutics (ALDX) had its "buy" rating reaffirmed by BTIG Research.
High
Report
Aldeyra Therapeutics (ALDX) had its "buy" rating reaffirmed by BTIG Research.
3/17
02:45 pm
aldx
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
Medium
Report
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
3/17
11:17 am
aldx
Aldeyra Therapeutics, Inc. [CNN]
Medium
Report
Aldeyra Therapeutics, Inc. [CNN]
3/17
10:54 am
aldx
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
High
Report
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
3/17
09:05 am
aldx
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease [Yahoo! Finance]
Medium
Report
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease [Yahoo! Finance]
3/17
08:30 am
aldx
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
High
Report
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
2/18
07:29 am
aldx
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/18
07:01 am
aldx
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Low
Report
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
12/30
06:27 pm
aldx
Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst [Seeking Alpha]
Low
Report
Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst [Seeking Alpha]
12/22
07:26 am
aldx
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist [Yahoo! Finance]
High
Report
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist [Yahoo! Finance]